Urszula C. P.
- Country
- Poland
- Department
- NA
Research Overview
- A Randomized, Double-Blind, Placebo-Controlled Study of AUR200 in Generalized Myasthenia Gravis
- Phase 3 Randomized Double-Blind Study of Orelabrutinib for Primary Progressive Multiple Sclerosis in Patients With PPMS
- Phase 3 Randomized Double‑Blind Study of Orelabrutinib vs Placebo on Disability Progression in Non‑Active Secondary Progressive Multiple Sclerosis
Data & Insights
Has run more than one trial at 278 of 496 partner sites.
Specializations
Neurology
The investigator specializes in treating chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on innovative therapeutic approaches for this rare autoimmune neurological condition that affects the peripheral nervous system.
- Autoimmune Neuropathies
- Peripheral Nerve Disorders
- Demyelinating Diseases
Their research interests include exploring novel subcutaneous treatment modalities for patients with chronic neurological conditions.
Immunology
The investigator focuses on autoimmune disorders affecting the nervous system, with particular emphasis on investigating targeted immunological therapies such as efgartigimod.
- Autoimmune Mechanisms
- Immunological Treatments
- Long-term Disease Management
Their work encompasses the development of innovative immunological interventions for chronic neurological conditions.
Treatment Innovation
The investigator explores advanced drug delivery systems, particularly subcutaneous administration methods for biological therapies in neurological conditions.
- Drug Delivery Systems
- Long-term Safety Assessment
- Treatment Efficacy Evaluation
Their research includes evaluating novel formulations to enhance treatment accessibility and patient comfort.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.